The most important number in the GLP-1 conversation is 14.9% — the average weight loss in the STEP-1 semaglutide trial. Everything else flows from it. It is the number that generated the headlines, reshaped clinical practice, and convinced millions of people to pursue GLP-1 treatment.
The second most important number is 11.9% — the average weight loss among patients who maintained GLP-1 treatment for one year in a real-world Cleveland Clinic study of 7,881 patients.
The gap between these two numbers — about 3 percentage points — is real, meaningful, and almost entirely explainable. Understanding it is not just intellectually interesting. It is practically useful, because the factors that create the gap are modifiable — and understanding them tells you what you can do to achieve results closer to the clinical trial end than the real-world average.
This article covers what the clinical trials actually measured, what real-world patients actually experience, what the gap is and why it exists, what patients report beyond the scale, and how to position yourself to achieve the best possible outcome from GLP-1 treatment.
The Clinical Trial Results: What Was Actually Measured
The STEP program: Semaglutide
The STEP clinical trial program for semaglutide (Wegovy) ran four phase 3 trials from 2018–2021. Here are the headline results:
| Trial | Population | Duration | Average Weight Loss |
|---|---|---|---|
| STEP-1 | Adults with obesity, no T2D | 68 weeks | 14.9% (9.6% placebo) |
| STEP-2 | Adults with obesity + T2D | 68 weeks | 9.6% (3.4% placebo) |
| STEP-3 | With intensive behavioral therapy | 68 weeks | 16.0% (5.7% placebo) |
| STEP-4 | Continued vs. switched to placebo | 68 weeks | Maintained 17.4% vs regained weight |
The STEP-1 figure of 14.9% is the most commonly cited benchmark for semaglutide. It represents the average across all participants who received 2.4 mg weekly semaglutide — including those who tolerated it less well, those who received less intensive lifestyle support, and those who did not fully adhere to the protocol.
The range behind the average: Averages obscure individual variation. In STEP-1, participants losing less than 5% of body weight and those losing more than 20% were both included in the 14.9% average. Approximately:
- 86.4% of semaglutide participants lost at least 5% of body weight
- 69.1% lost at least 10%
- 50.5% lost at least 15%
- 32% lost at least 20%
This means roughly 1 in 3 people who received semaglutide in the STEP-1 trial lost 20% or more of their body weight. That result is what drives the social media accounts showing dramatic before-and-after photographs — those patients are real and their outcomes are genuine. They are also the high responders, not the median.
The SURMOUNT program: Tirzepatide
The SURMOUNT trials for tirzepatide (Zepbound) produced higher average weight loss numbers than the STEP semaglutide trials, with the dual GLP-1/GIP mechanism producing stronger appetite suppression and energy expenditure effects:
| Trial | Population | Duration | Average Weight Loss (15mg) |
|---|---|---|---|
| SURMOUNT-1 | Adults with obesity, no T2D | 72 weeks | 20.9% |
| SURMOUNT-2 | Adults with obesity + T2D | 72 weeks | 13.4% |
| SURMOUNT-3 | After intensive lifestyle run-in | 72 weeks | 26.6% from pre-baseline |
The SURMOUNT-1 figure of 20.9% at the highest dose is the most remarkable in obesity pharmacotherapy history — the first medication to approach bariatric surgery-level outcomes. Approximately 57% of participants at 15 mg lost 20% or more of their body weight; 31.6% lost 25% or more.
SURMOUNT-5: The head-to-head
Published in the New England Journal of Medicine, SURMOUNT-5 was the first randomized head-to-head trial directly comparing semaglutide and tirzepatide in the same population. At 72 weeks, tirzepatide produced 20.2% average weight loss versus 13.7% for semaglutide — a 47% relative advantage for tirzepatide. This trial settled the question of which medication is more effective on average, while confirming that both produce clinically meaningful results.
What clinical trials are — and are not
Understanding clinical trial results requires understanding what they measure and how:
Highly selected populations: Trials enroll participants who meet specific inclusion and exclusion criteria. STEP-1 excluded patients with type 2 diabetes, recent cardiovascular events, serious psychiatric illness, substance abuse disorders, and multiple other conditions. The trial population is healthier and more selected than a real-world clinical population.
Intensive support structures: Trial participants receive regular clinical contact, structured lifestyle counseling, motivational support, and careful monitoring that is typically much more intensive than what patients receive in telehealth GLP-1 programs. This support structure contributes to better adherence and therefore better outcomes.
Protocol-mandated dosing: Trials push participants to the target dose (2.4 mg semaglutide, 15 mg tirzepatide) at a standardized pace. In the real world, many patients stay at lower doses — either by choice, due to side effects, or due to provider inertia.
Minimum discontinuation: Trials are designed to maximize completion rates. Participants are motivated, supported, and compensated. The context is fundamentally different from paying out of pocket for a telehealth subscription.
Efficacy estimand vs. treatment policy estimand: Clinical trials report both. The efficacy estimand (what happens if you stay on the drug) typically shows higher weight loss than the treatment policy estimand (what happens to everyone regardless of adherence). Most published trial headlines use the treatment policy estimand, which includes dropouts — meaning even the 14.9% figure already partially accounts for some discontinuation.
The Real-World Results: What Research Shows
The Cleveland Clinic Study: 7,881 patients, one year
The most comprehensive real-world analysis of GLP-1 outcomes to date was published in June 2025 in the journal Obesity, examining electronic health records from 7,881 adults with obesity treated at Cleveland Clinic's Ohio and Florida centers from 2021–2023.
Key findings:
Average weight loss at one year (treatment maintainers): 11.9% — meaningful, but approximately 3 percentage points below the STEP-1 trial average of 14.9%.
The primary explanation for the gap: Higher rates of treatment discontinuation and lower maintenance doses than in trials.
- More than 80% of patients were using doses below the target maintenance dose (2.4 mg semaglutide or 15 mg tirzepatide) for the longest portion of their treatment period
- Discontinuation rates were significantly higher than in trials
The surprising finding on weight regain: Patients who discontinued GLP-1 treatment in the real world did not experience the rapid, dramatic weight regain seen in clinical trial withdrawal studies. Their weight remained relatively stable after stopping. The researchers noted this contrasted sharply with what was observed after medication discontinuation in trials, and may reflect that real-world patients engage in alternative weight management efforts — dietary changes, exercise programs, other interventions — after stopping.
The highly adherent subset
A critical finding from the real-world evidence base: outcomes approach clinical trial results when focusing on highly adherent patients. A PubMed narrative review of multiple real-world studies concluded directly: "Outcomes approach those seen in trials when focusing on highly adherent patients."
This is the most important sentence in the real-world evidence summary. The gap between trials and real-world results is predominantly a function of adherence — specifically, dose and duration. Patients who reach and maintain the target therapeutic dose for the duration comparable to trials produce results comparable to trials.
This is not an abstraction. It is a practical statement about what you can control.
The telehealth-specific data
A 2026 retrospective analysis of 572 self-pay telehealth patients found that semaglutide delivered weight loss outcomes comparable to the STEP-1 trial results in that setting. Notably, the superiority of tirzepatide over semaglutide seen in the SURMOUNT-5 trial was not replicated in this cohort — a finding the authors attributed to patients in the self-pay telehealth setting remaining at lower tirzepatide doses for cost reasons, rather than escalating to the higher doses where tirzepatide's advantage is most pronounced.
This finding has direct implications: if you are on tirzepatide primarily for its superior efficacy data, that superiority is dose-dependent. Cost-driven decisions to stay at lower doses may eliminate the advantage relative to semaglutide.
Why Results Vary So Much Between Individuals
Even within clinical trials — where dosing and support are maximized — there is enormous individual variation. Understanding the drivers of this variation helps manage expectations and identify what is within your control.
Factors within your control
Adherence to the full titration schedule: Getting to and staying at the therapeutic maintenance dose is the single most powerful predictor of outcomes. Patients who stop at the 1 mg semaglutide dose never experience the full appetite suppression that the 2.4 mg dose produces. Every incremental dose increase produces incremental additional benefit.
Protein intake and resistance training: As covered in our exercise article, the composition of weight loss (fat vs. muscle) is substantially influenced by diet quality and exercise. Patients who prioritize protein and resistance training both preserve more muscle and often achieve better total weight loss because muscle preservation supports metabolic rate.
Dietary quality within reduced appetite: GLP-1 medications suppress appetite — they do not direct what you eat. Patients who use the reduced appetite to eat high-quality protein-forward diets achieve better body composition outcomes than those who eat smaller quantities of lower-quality food. The medication creates an opening; what you do with it determines the result.
Alcohol and calorie-dense beverage consumption: Liquid calories are not subject to GLP-1-mediated appetite suppression. Patients who continue drinking alcohol or calorie-dense beverages at pre-medication levels are partially offsetting the caloric deficit the medication creates.
Sleep and stress management: Cortisol and sleep deprivation both impair the metabolic response to GLP-1 treatment. Chronic sleep restriction (less than 6 hours per night) significantly impairs weight loss and increases the proportion of weight lost from lean mass. These factors are within your control, even if they are challenging to optimize.
Factors partially within your control
Dose and medication selection: Your provider determines the titration schedule, but you can advocate for escalation to the target dose if you are tolerating lower doses well. If you have plateaued at a lower dose and are tolerating the medication, asking your provider about escalating to the next level is appropriate and often productive.
Provider quality and support: The level of clinical oversight, coaching, and follow-up you receive significantly affects adherence. Providers who check in regularly, proactively address side effects, and adjust doses promptly produce better outcomes than those who prescribe and disappear. Choosing a platform with stronger clinical support is within your control at enrollment.
Factors largely outside your control
Biological response variability: Some patients are high responders — they experience dramatic appetite suppression and weight loss at lower doses. Others are moderate responders who achieve meaningful but less dramatic results even at maximum dosing. This individual variation is real and reflects differences in GLP-1 receptor density, baseline gut motility, metabolic rate, and other factors that are not predictable from any baseline characteristic.
Genetic and hormonal factors: Thyroid function, cortisol regulation, sex hormone levels, and genetic variants in appetite regulation all affect individual response. These are modifiable only through separate medical management.
Starting weight and degree of obesity: Patients with higher starting BMIs typically lose more absolute weight but similar percentages. Patients close to the BMI threshold for qualification sometimes see less dramatic percentage changes.
What Patients Report Beyond the Scale
The clinical trial data captures weight loss. Patient-reported experiences capture something richer — and often more motivating for people starting treatment.
Food noise reduction
One of the most consistently reported experiences among GLP-1 patients is the reduction or elimination of "food noise" — the constant mental preoccupation with food that many people with obesity describe. The relentless internal commentary about what to eat next, when the next meal is, how to avoid certain foods, the guilt and planning around eating. For many patients, this background noise simply goes quiet on GLP-1 treatment.
This is not a placebo effect. It reflects the direct central nervous system action of semaglutide and tirzepatide in the areas of the brain that regulate hunger signaling and food-related reward. The subjective experience of food losing its psychological hold is pharmacologically real.
Patients frequently report this as more life-changing than the weight loss itself — the mental freedom from food preoccupation that they had not expected and had not experienced in decades, if ever.
Reduced alcohol desire
As covered in our alcohol article, a significant proportion of GLP-1 patients report spontaneously drinking less without making a conscious decision to cut back. The same reward circuitry that drives food preoccupation also drives alcohol desire — and GLP-1 receptor activation in these areas reduces both.
Changes in food preferences
Many patients report that foods that previously felt irresistible — highly processed, sweet, fatty foods — lose their appeal. Healthier foods become more attractive by comparison. This shift in preference, while anecdotally reported, aligns with what is known about GLP-1's effects on the brain's food reward system and represents a potentially durable change rather than a temporary willpower intervention.
Cardiovascular and metabolic improvements
The SELECT trial (Wegovy cardiovascular outcomes data) showed a 20% reduction in major adverse cardiovascular events in patients with established cardiovascular disease. Beyond weight loss, GLP-1 medications directly reduce blood pressure, improve cholesterol profiles, improve insulin sensitivity, reduce inflammation, and produce kidney-protective effects that are beginning to be documented in clinical research.
Real-world patients with type 2 diabetes or prediabetes frequently report normalized blood sugar, reduced medication needs, and A1C improvements that occur rapidly — often within weeks of starting treatment — before major weight loss has occurred. These metabolic effects are not dependent on weight loss reaching the 15% threshold; they begin accumulating from the early weeks of treatment.
Improved mobility and quality of life
Even the moderate real-world average of 11.9% weight loss represents a clinically significant change in physical capacity. Reduced joint pain, improved mobility, easier physical activity, better sleep quality (often driven by improved sleep apnea severity), and reduced daily fatigue are consistently reported alongside the weight changes.
Patient-reported quality of life scores in clinical trials showed substantial improvements in physical functioning, self-esteem, and mental health that matched or exceeded what the weight loss numbers alone would predict. The medication's central effects on mood, energy, and food relationship appear to contribute quality of life benefits beyond the mechanical effects of weight reduction.
The Gap Explained: A Practical Summary
The real-world versus clinical trial gap (approximately 11.9% vs. 14.9% for semaglutide) is explained by three factors, in order of importance:
1. Early discontinuation: Real-world studies consistently show 20–50% of patients discontinue within the first year, compared to much lower rates in trials. Every patient who stops at month 3 or 4 — before reaching maintenance dose and the full treatment effect — reduces the cohort average. The most important thing you can do for your own outcome is stay on the medication through the titration period.
2. Lower maintenance doses: More than 80% of real-world patients in the Cleveland Clinic study used doses below the target maintenance level for the majority of their treatment. The medication's effect is dose-dependent. Patients at 1 mg semaglutide are getting less appetite suppression than patients at 2.4 mg. The gap from lower dosing is real and compounding over time.
3. Less intensive support: Clinical trial participants received regular contact with research teams, structured lifestyle counseling, and motivational support. Real-world patients — particularly those in async telehealth programs — receive far less. Support quality affects adherence, which affects outcomes.
What this tells you: The gap is not primarily biological. It is primarily behavioral — and behavioral factors are within your influence. The patients who achieve trial-level results in the real world do so by staying on the medication at effective doses with adequate clinical support.
Setting Your Own Expectations
Rather than aiming for a specific percentage, here is a more useful framing for what to expect:
If you stay on medication at the target therapeutic dose for 12+ months with adequate protein and some resistance training: Results approaching clinical trial outcomes are achievable. Some patients achieve more than the trial average; most achieve something close.
If you discontinue early or stay at subtherapeutic doses: Expect results proportionally below the trial averages.
If you are on tirzepatide and have stayed at starter doses for cost reasons: You may be experiencing some of semaglutide's effect without tirzepatide's full advantage. Discuss dose escalation with your provider if cost and tolerability allow.
Month by month, realistically:
| Timeline | Typical Real-World Weight Loss |
|---|---|
| Month 1 (starting dose) | 1–3 lbs — sub-therapeutic dose |
| Month 3 (mid-titration) | 5–10% of starting weight |
| Month 6 (approaching maintenance) | 8–14% of starting weight |
| Month 12 (maintained at target dose) | 10–18% of starting weight |
| Month 18–24 (continued treatment) | 12–22%+ for high adherence patients |
The wide ranges reflect real individual variation. They are not excuses — they are the honest envelope within which most patients' outcomes fall.
One final data point: Among patients in real-world studies who were highly adherent and reached maintenance dosing, outcomes consistently approached the 15–20% range seen in clinical trials. The gap between trials and reality is real — but it is not inevitable.
How to Maximize Your Own Results
Synthesizing everything in this article into practical guidance:
1. Get to and stay at the maintenance dose. This is the single highest-leverage action. Every dose increase brings more appetite suppression and faster fat loss. If you have been at 1 mg semaglutide for four months and are tolerating it, ask your provider about escalating.
2. Prioritize protein at every meal. Target 1.2 g/kg body weight per day. Use protein shakes to supplement on low-appetite days. Eat protein first at every meal before anything else on the plate.
3. Do resistance training 2–3 times per week. The medication does the work on fat. Resistance training does the work on muscle preservation. Both are necessary for optimal body composition.
4. Choose a provider with ongoing clinical support. Regular check-ins, proactive side effect management, and dose adjustment support improve adherence. Adherence drives outcomes.
5. Address the non-scale factors. Sleep, stress management, and alcohol intake all affect metabolic response to GLP-1 treatment in ways the scale captures only indirectly.
6. Do not use month one as a prediction. The starting dose is sub-therapeutic. Month one weight loss of 1–3 lbs is not predictive of what the medication will do at month six at the maintenance dose. The patients who discontinue in month one because "it isn't working" never experience the medication's actual therapeutic effect.
7. Adjust expectations for your actual situation, not the trial average. If you have type 2 diabetes, your weight loss will likely be less than the STEP-1 figure (which excluded T2D patients) and more like the STEP-2 figure. If you are on tirzepatide, your ceiling is higher than on semaglutide — but only if you reach the doses where tirzepatide's advantage is realized. Knowing your specific clinical context helps calibrate the right expectations.
The clinical trial results are real. They are achievable in the real world. The gap between what trials show and what average real-world patients experience is not primarily about the medication — it is primarily about adherence, dosing, and support. All three are within your influence.